News | September 26, 2007

PET Better than Mammography, US in Breast Treatment Response

September 27, 2007 - Researchers in Australia have shown that positron emission tomography (PET) that uses a radioactive sugar molecule is more useful than mammography and ultrasound in predicting a breast tumor’s response to chemotherapy and, therefore, the patient’s ultimate likelihood of survival.

In research presented at the European Cancer Conference (ECCO 14) in Barcelona, Vinod Ganju, M.D., Monash Oncology Research Institute (MORI) and Monash Breast Cancer Research Consortium, Monash Medical Centre, Melbourne, Australia, reported that when the scanning procedure was used to measure the accumulation of radioactive glucose fluorodeoxyglucose (FDG) in tumor tissue from patients with locally-advanced breast cancer before and after preoperative chemotherapy, women who had the highest accumulation at the beginning and who then had the highest percentage drop in accumulation after four cycles of chemotherapy were more likely to have a complete response to their treatment - no tumor cells remaining in the final tumor resection specimen. However, measurements taken using mammography or ultrasound were not able to predict a pathological response accurately.

This study suggests that tumors with high initial standard uptake values (SUVs) seem to be more sensitive to chemotherapy, thereby giving a better chance of achieving a reduction or complete removal of the cancer.

Dr Ganju said: “In our study, we were able to show that patients who had higher baseline SUVs and a greater reduction in SUV at the second PET scan, were more likely to respond to the chemotherapy and achieve a complete pathological response. Patients who achieve a complete pathological response are more likely to survive and have a better prognosis.”

The researchers recruited 47 women with locally advanced breast cancer to their study, and they were able to evaluate data from 44 of these women. The patients were randomly assigned to receive either fluorouracil, epirubicin, cyclophosphamide (FEC) followed by docetaxel, or docetaxel followed by FEC. They were assessed at the start by PET scans, physical examination, mammography, ultrasound and tumor biopsy, and again after four cycles of chemotherapy. The initial SUVs and the percentage reduction in SUVs after chemotherapy were correlated to pathological response (complete, partial or no response) as assessed by examination of biopsy samples.

Nine women had a complete pathological response (pCR), 15 had a partial response (pPR) and 20 less than optimal pathological response (NR) to chemotherapy. Women who had a pCR were significantly more likely to have higher SUVs before chemotherapy than NR women (an average of 9.7 versus 6.4 on the SUV measurement scale). The percentage reduction in SUVs after chemotherapy was also significant, with SUVs in pCR women reducing by an average of 83.3 percent compared to 50.4 percent in NR women.

Dr Ganju said: “This study shows that women with high baseline SUVs and a higher percentage reduction of SUVs after four cycles of chemotherapy are more likely to achieve a pathological complete response to neoadjuvant chemotherapy. FDG-PET appears to be an important addition to conventional imaging of women with breast cancer and may contribute significantly to a more individualized management of their disease. Currently, all patients receive the same chemotherapy regardless of their tumor characteristics. It would be very valuable to target therapies according to baseline tumor characteristics. This could spare the patient unnecessary on-going chemotherapy, or enable them to switch to a different therapy if the first was found to be ineffective.”

PET technology is advancing all the time. “Different tracer molecules other than glucose are available for PET studies. These may prove even more useful in the future, but most are still in the experimental stages,” concluded Dr Ganju. The group is also currently correlating the results from this study with the genetic profile of the tumors.

For more information: http://www.ecco-org.eu

Related Content

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Overlay Init